A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours

ISSN： 0114-5916

Source： Drug Safety, Vol.32, Iss.11, 2009-11, pp. : 1001-1015

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

By Theou-Anton Nathalie Faivre Sandrine Dreyer Chantal Raymond Eric

Drug Safety, Vol. 32, Iss. 9, 2009-09 ,pp. : 717-734

Adis International

Access to resources Recommend Favorite

Imatinib Mesylate: In the Treatment of Gastrointestinal Stromal Tumours

By Croom K.F. Perry C.M.

Drugs, Vol. 63, Iss. 5, 2003-01 ,pp. : 513-522

Adis International

Access to resources Recommend Favorite

Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then?

By Nilsson Bengt Nilsson Ola Ahlman Håkan

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 457-468

Informa Healthcare

Access to resources Recommend Favorite

Imatinib mesylate in the treatment of chronic myeloid leukaemia

By Druker Brian J

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 963-971

Informa Healthcare

Access to resources Recommend Favorite

Imatinib: A Review of its Use in Chronic Myeloid Leukaemia

By Moen Marit D. McKeage Kate Plosker Greg L. Siddiqui M. Asif A.

Drugs, Vol. 67, Iss. 2, 2007-01 ,pp. : 299-320

Adis International

Access to resources Recommend Favorite